Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
accessible, ACCO, ACTH, adrenocorticotropic, agency, antihypertensive, assist, autoimmune, awaiting, award, broad, channel, chronic, clinical, comparison, conference, Consent, declaratory, Delaware, demonstration, denying, disposition, divest, efficacy, encourage, extensive, force, FTC, hire, hypertension, infrastructure, infringed, Injection, invalid, Mallinckrodt, Nebivolol, nephrotic, ongoing, platform, promotion, Propranolol, protein, proxy, purified, pursue, RA, Repository, rheumatoid, routinely, sequentially, syndrome, Treprostinil, unmet, unrelated, unsuccessful, unused, upcoming, website
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view